Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03155620 · ADVERSE EVENTS

Adverse events

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · Source last updated 2026-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
The reporting timeframe includes adverse events occurring within 14 days following a biopsy performed after enrollment on this study. All-Cause Mortality monitored/assessed up to 5 years.
Other-event reporting threshold
0%

Biopsy related AE reporting is collected routinely using case report forms. The SAE table reflects biopsy related CTCAEs submitted by the institution via expedited reporting (NCI AdEERs / CAeRs). All remaining biopsy related CTCAEs collected by means other than expedited reporting are non-serious and are reported in the "AE Other" table. Patients enrolled after Stage 1 (12/31/21) are excluded from AE reporting. All-Cause Mortality includes all deaths collected on the study for enrolled patients.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.

2 / 13431 / 1343906 / 1377

Group identifiers: EG000: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Infections and infestations - Other, specify
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Meningitis
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Respiratory, thoracic and mediastinal disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Laryngeal edema

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Nervous system disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Headache
Complete source fields
description
Biopsy related AE reporting is collected routinely using case report forms. The SAE table reflects biopsy related CTCAEs submitted by the institution via expedited reporting (NCI AdEERs / CAeRs). All remaining biopsy related CTCAEs collected by means other than expedited reporting are non-serious and are reported in the "AE Other" table. Patients enrolled after Stage 1 (12/31/21) are excluded from AE reporting. All-Cause Mortality includes all deaths collected on the study for enrolled patients.
event Groups
  1. deaths Num Affected
    906
    deaths Num At Risk
    1377
    description
    Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.
    id
    EG000
    other Num Affected
    1
    other Num At Risk
    1343
    serious Num Affected
    2
    serious Num At Risk
    1343
    title
    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
frequency Threshold
0
other Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Nervous system disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Headache
serious Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Infections and infestations - Other, specify
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Meningitis
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Respiratory, thoracic and mediastinal disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      1343
    term
    Laryngeal edema
time Frame
The reporting timeframe includes adverse events occurring within 14 days following a biopsy performed after enrollment on this study. All-Cause Mortality monitored/assessed up to 5 years.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice